Skip to Content
Tracy M Downs, MD, FACS

Contact Dr. Downs

E-mail:
downs@urology.wisc.edu

Phone:
(608) 263-9534

Mail:
UW Medical Foundation Centennial Building
1685 Highland Ave
Madison, WI 53705-2281

Tracy M Downs, MD, FACS

Associate Professor (CHS)
Director, Bladder Cancer and Intravesical Therapy Programs

Education

  • MD, University of California-San Diego, La Jolla, CA, 1993
  • Internship, Brigham and Women’s Hospital (Harvard), Boston, MA, 1995
  • Clinical Nutrition Fellowship, Harvard, Boston, MA, 1999
  • Residency, Brigham and Women’s Hospital (Harvard), Boston, MA, 2001
  • Research Fellowship, University of California-San Francisco, San Francisco, CA, 2003
  • Urologic Oncology Fellowship, University of California-San Francisco, San Francisco, CA, 2003

Clinical Specialties

Dr. Downs is certified by the American Board of Urology. He specializes in the surgical treatment of urologic cancers and treats all forms of urologic cancers including bladder cancer, prostate cancer, kidney cancer, testis cancer and penile cancer. He has a special interest in the treatment of bladder cancer, where he performs robotic cystectomy (da Vinci robotic system), along with complex urinary reconstruction to make a new internalized bladder (orthotopic neobladder). Dr. Downs’ clinical care philosophy is to provide compassionate, cutting-edge urologic cancer care to his patients.

Research Interests

Dr. Downs has a joint appointment with the UW Carbone Cancer Center, and his clinical research emphasizes developing new therapies for genitourinary cancers.

Research Focus
Chemoprevention – Bladder cancer, prostate cancer
Screening Programs – Bladder cancer screening for high-risk subjects
Outcomes Research – Patient outcomes of treatments for non-muscle invasive (superficial) bladder cancer and radical cystectomy
Translational Research – Discovery of molecular and urinary biomarkers (bladder cancer)
Quality of Life Outcomes – Bladder cancer, prostate cancer

Recent Publications
  • Rush PS, Shiau JM, Hibler BP, Longley BJ, Downs TM, Bennett DD. Primary cutaneous adenosquamous carcinoma of the penis: the first characterization of HPV status in this rare and diagnostically challenging entity with review of glandular carcinomas of the penis. J. Cutan. Pathol. 2016 Dec; 43(12):1226-1230.
    [PubMed ID: 27696488]
    More Information
  • Blute ML, Ziemlewicz TJ, Lang JM, Kyriakopoulos C, Jarrard DF, Downs TM, Grimes M, Shi F, Mann MA, Abel EJ. Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology 2016 Sep 22.
    [PubMed ID: 27667156]
    More Information
  • Lane GI, Downs TM, Soubra A, Rao A, Hemsley L, Laylan C, Shi F, Konety B. Tolerability of Repeat Use of Blue Light Cystoscopy with Hexaminolevulinate for Patients with Urothelial Cell Carcinoma. J. Urol. 2016 Sep 21.
    [PubMed ID: 27664580]
    More Information
  • Blute ML, Shiau JM, Truong M, Shi F, Abel EJ, Downs TM, Jarrard DF. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer. World J Urol 2016 Sep 15.
    [PubMed ID: 27631325]
    More Information
  • Grimes MD, Blute ML, Wittmann TA, Mann MA, Zorn K, Downs TM, Shi F, Jarrard DF, Best SL, Richards KA, Nakada SY, Abel EJ. A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery. Urology 2016 Oct; 96():93-98.
    [PubMed ID: 27339026]
    More Information
  • Blute ML, Zorn K, Grimes M, Shi F, Downs TM, Jarrard DF, Best SL, Richards K, Nakada SY, Abel EJ. Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer. BJU Int. 2016 Sep; 118(3):399-407.
    [PubMed ID: 26589741]
    More Information
  • Downs TM. Editorial Comment. J. Urol. 2016 Feb; 195(2):412.
    [PubMed ID: 26592567]
    More Information
  • Blute ML, Abel EJ, Downs TM, Kelcz F, Jarrard DF. Addressing the need for repeat prostate biopsy: new technology and approaches. Nat Rev Urol 2015 Aug; 12(8):435-44.
    [PubMed ID: 26171803]
    More Information
  • Blute ML, Rushmer TJ, Shi F, Fuller BJ, Abel EJ, Jarrard DF, Downs TM. Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer. J. Urol. 2015 Nov; 194(5):1214-9.
    [PubMed ID: 26173101]
    More Information
  • Potretzke AM, Wong KS, Shi F, Christensen W, Downs TM, Abel EJ. Highest risk of symptomatic venous thromboembolic events after radical cystectomy occurs in patients with obesity or nonurothelial cancers. Urol Ann 2015 Jul-Sep; 7(3):355-60.
    [PubMed ID: 26229325, PMCID: 4518374]
    More Information


webmaster@surgery.wisc.edu Copyright © 2016 The Board of Regents of the University of Wisconsin System